Jairo Gooskens, etc.,al. Prolonged Influenza Virus Infection during Lymphocytopenia and Frequent Detection of Drug‐Resistant Viruses. The Journal of Infectious Diseases 2009;199:1435–1
The factors that cause prolonged human influenza virus respiratory tract infection and determine its clinical impact and the development of drug‐resistant viruses are unclear. During a 3‐year period, symptomatic influenza virus excretion for 2 weeks was observed among 8 immunocompromised patients and found to be associated with lymphocytopenia at onset (8 of 8 patients) more often than with granulocytopenia (2 of 8 patients) or monocytopenia (2 of 8 patients). Six (75%) of 8 patients developed influenza lower respiratory tract infection (10 episodes), and receipt of oseltamivir treatment was significantly associated with clinical improvement (8 of 8 episodes vs. 0 of 2 untreated episodes; ). Complete viral clearance was strongly correlated with lymphocyte reconstitution ( ) but was never observed during the first 2 weeks after oseltamivir treatment. Neuraminidase inhibitor–resistant influenza viruses emerged in 2 (67%) of 3 patients eligible for resistance analysis. In conclusion, prolonged influenza virus infection was associated with lymphocytopenia, influenza lower respiratory tract infection, and frequent development of drug resistance during antiviral therapy. Clinical improvement in influenza lower respiratory tract infection is observed during oseltamivir treatment, but complete viral clearance is dependent on lymphocyte reconstitution, irrespective of receipt of antiviral medication.
See Also:
Latest articles in those days:
- Global pattern and determinant for interaction of seasonal influenza viruses 14 hours ago
- Spatio-temporal dynamics and drivers of highly pathogenic avian influenza H5N1 in Chile 2 days ago
- [preprint] Avian Influenza Virus Infections in Felines: A Systematic Review of Two Decades of Literature 2 days ago
- Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe 2 days ago
- Assessment of potential adverse events following the 2022-2023 seasonal influenza vaccines among U.S. adults aged 65 years and older 2 days ago
[Go Top] [Close Window]